Multiple Sclerosis
Conference Coverage
Real-world MS relapse rate is low for dimethyl fumarate
Key clinical point: Comparison of five disease-modifying therapies for MS has revealed the lowest relapse rate for dimethyl fumarate, which should...
Conference Coverage
Alemtuzumab beneficial for MS patients of African descent
Key clinical point: Alemtuzumab had clinical and radiologic benefits in patients of African descent with active RRMS. Major finding: No evidence...
Conference Coverage
Exercise improves sleep and may improve cognitive/physical function in MS
Moderate-intensity exercise may benefit MS patients in terms of improved sleep and perhaps improved cognitive and physical function.
Conference Coverage
Real-world data favor dimethyl fumarate, fingolimod for MS
Key clinical point: In real-world care, dimethyl fumarate and fingolimod appear more effective than other disease-modifying therapies for MS....
Conference Coverage
Oral contraceptive efficacy unaffected by dimethyl fumarate
Key clinical point: Delayed-release dimethyl fumarate can be used in childbearing women with RRMS without fear of compromising the effect of a...
Conference Coverage
Teriflunomide effective for faster-advancing MS
Key clinical point: Teriflunomide is effective for patients with faster-advancing MS. Major finding: Teriflunomide at 14 mg and 7 mg reduced the...
Conference Coverage
Smoking causes worse outcome in MS
Key clinical point: Smoking increases the risk of developing multiple sclerosis and worsens the severity of the disease. Major finding: Regular...